eAppendix 1. Exclusion Criteria 1. Inability to swallow medication. 2. CVT associated with central nervous system infection. 3 . CVT due to head trauma. 4. Planned surgical treatment for CVT (eg, decompressive surgery, ear-nose-throat surgery). 5. Conditions associated with increased risk of bleeding, such as: a) Major surgery in the month prior to Visit 1 b) Planned major surgery or intervention in the next 6 months c) History of intraocular, spinal, retroperitoneal, or atraumatic intra-articular bleeding, unless the causative factor has been permanently eliminated or repaired d) Gastrointestinal hemorrhage within the past 6 months (prior to Visit 1), unless the cause has been permanently eliminated or repaired, or endoscopically documented gastroduodenal ulcer disease in the previous 30 days prior to Visit 1 e) Hemorrhagic disorder or bleeding diathesis, eg, history of thrombocytopenia or platelet count <100 000/mL at screening, von Willebrand disease, hemophilia A or B or other hereditary bleeding disorder, history of prolonged bleeding after surgery/intervention f) Fibrinolytic agents within 48 hours of starting trial medication. Pre-randomization interventional treatment (i.v. r-tPA or urokinase and/or stenting) is neither required nor excluded provided that the start of trial medication is at least 48 hours after the application of any fibrinolytic agent g) Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg) h) History of intracranial aneurysm (unless it was permanently resolved with either clipping or coiling at least 1 year prior to the study entry). 6. Life-threatening or major bleeding (per International Society for Thrombosis and Haemostasis criteria), other than intracerebral hemorrhage due to the index CVT, during the 6 months prior to, or while on anticoagulants during the acute phase of CVT. 7. History of symptomatic non-traumatic intracerebral hemorrhage with risk of recurrence (including hemorrhagic stroke within 6 months prior to screening, but other than intracerebral hemorrhage during the acute phase of CVT). 8. Severe renal impairment defined as creatinine clearance (calculated by Cockcroft-Gault equation) <30 mL/min at screening, or if the Investigator expects creatinine clearance is likely to drop below 30 mL/min during the course of the study. 9. Patients who require taking GPIIb/IIIa antagonists, rivaroxaban, apixaban, and edoxaban, or other oral anticoagulants, systemic ketoconazole, itraconazole, posaconazole, cyclosporine, tacrolimus and dronedarone, rifampicin, carbamazepine, phenytoin, and St John's Wort. 10. Patients receiving treatment with warfarin, dabigatran etexilate, or other antithrombotic regimen (ie, anticoagulants or antiplatelet medication) for an indication other than CVT and requiring continuation of that treatment for the original diagnosis without change in the regimen. 11. Patients with prosthetic heart valves. 12. Known hypersensitivity to dabigatran etexilate or warfarin, or to any of the excipients of either product. 13. Any current or recent malignancy (≤6 months prior to Visit 1) unless the malignancy was a basal cell carcinoma that was completely removed. 14. Concomitant disease that increases the risk of an adverse reaction to study interventions or that has life expectancy <6 months. 15. Premenopausal women (last menstruation ≤1 year prior to Visit 1) who are pregnant or breastfeeding, or who plan to become pregnant while in the trial. 16. Patients who have participated in another trial with an investigational drug or device within the 14 days preceding Visit 1, or who currently are participating in another trial. Patients who are still experiencing a clinical effect from an investigational drug. 17. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study or at the end of the study. 18. Any condition the Investigator believes would not allow safe participation in the study. 19. Active liver disease, as indicated by ≥1 of the following: a) Prior and persistent alanine aminotransferase or aspartate transaminase, or alkaline phosphatase >3× upper limit of normal 
eAppendix 2. MRI Protocol
Measurements at the end of treatment were performed at a minimum field strength of 1.5 T.
• For any parallel imaging technique (GRAPPA, ASSET …), an acceleration factor of 2 was used • Wherever "Slice orientation: transverse" was indicated, this was according to bicommissural line Collection of post-study anticoagulation information X Vital status collection X Completion of patient participation q,r X X a Signing of informed consent and subsequent screening was done after the diagnosis of CVT had been established, treatment with parenteral anticoagulation had started, and the patient was considered to be stable. A fictitious day number (Day −1) has been assigned to the screening visit (Visit 1). b Day of randomization. Could be performed on the same day as Visit 1. In that case, Visit 2 procedures that were performed as part of Visit 1 were not repeated. c EOT and follow-up procedures (Visits 5 and 6) were performed for all patients at the time of discontinuation of trial medication. This included patients who discontinued trial medication prior to Day 169. d Extended follow-up applied only to patients who discontinued trial medication early. e Re-consenting might have been necessary when new relevant information became available and was conducted according to the instructions of the sponsor (Boehringer Ingelheim). f National Institute of Health Stroke Scale (NIHSS). g Height was measured at screening only. h Pregnancy tests required for all women of childbearing potential. The test at Visit 1 was performed after informed consent had been obtained. i In addition to the tests performed at the visits, women of childbearing potential were supplied with pregnancy tests and instructed to perform pregnancy testing every 4 weeks when visits were more than 4 weeks apart. j At screening, imaging was not performed specifically for the trial. The imaging that was done for diagnosis of the cerebral venous or dural sinus thrombosis was used and was submitted for review by the trial's AC. k At EOT, the assessment of recanalization was done by MRI and MR venography. An MRI protocol was provided as part of the ISF and was followed for the EOT imaging. The EOT images were submitted for review by the AC. l Throughout the trial, whenever routine imaging was performed due to worsening of the patient's condition, a suspected new intracranial hemorrhage, or a new VTE, those images were made available to the trial's AC for independent blinded review. m EOT assessment of intracranial hemorrhage was done by MRI. n Assessment of INR for patients who were on a VKA prior to randomization. At least 1 measurement prior to start of trial treatment was done in order to determine when to stop initial parenteral therapy and when to start trial treatment. o Assessment of INR for patients randomized to warfarin. Daily INR measurements were performed from just prior to start of treatment until concomitant heparin treatment was stopped. INR measurements were then taken at least every 2 weeks for the first 3 months and monthly thereafter. p At Visit 2, information is collected on any new VTEs since signing of consent. q Completion of patient participation. Patients who completed the full treatment period of 169 days completed their participation at the follow-up visit (Visit 6). r Completion of patient participation. Patients who discontinued trial medication early after the follow-up visit were followed for survival, for major bleeding events, VTE events and any other adverse events until Day 176 (25 weeks) after randomization. They completed participation at that moment. 
Cerebral venous recanalization
Cerebral venous recanalization was assessed following the thrombus load concept: 1 1. At baseline and at the end of treatment, occlusion of individual cerebral veins and sinuses were scored as follows: 1 = full occlusion; 0 = no occlusion or partial occlusion. 2. This score was applied to each of the veins and sinuses: superior sagittal sinus, straight sinus, cavernous sinus, left jugular vein, and right jugular vein were each scored individually (ie, each was scored as either 0 or 1); right lateral transverse and sigmoid sinus were scored together (ie, 0 points if neither is fully occluded; 1 point if at least 1 of them is fully occluded); left lateral transverse and sigmoid sinus were scored together; superior petrous sinus and inferior petrous sinus were scored together; deep venous system was scored as a group, irrespective of the number of occluded veins (ie, 0 points if none is fully occluded; 1 point if at least 1 is fully occluded); superficial cortical veins were scored as a group, irrespective of the number of occluded veins; cerebellar veins were scored as a group system, irrespective of the number of occluded veins. 3. For each individual patient a total score (thrombus load) was calculated at baseline and at the end of treatment. 4. A recanalization score was calculated for each patient as the difference between the baseline total score and the end-of-treatment total score.
New hemorrhagic brain lesion or worsening of the hemorrhagic component of a baseline lesion
• This was assessed by comparing repeated neuroimaging that is routinely performed if the patient has a neurological worsening during the trial, or at the end-of-treatment visit, to the baseline image (ie, to the neuroimaging that established the diagnosis of CVT). The comparison of images and the categorization of the lesions was done by the adjudication committee. • Hemorrhagic brain lesions at baseline and during treatment/at end-of-treatment visit were categorized as indicated on p.10, according to the definitions as recommended by von Kummer et al (2015). 2 Any new hemorrhagic brain lesion was categorized as Class 3 (intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage). If there was more than 1 hemorrhagic lesion present on imaging, the category of the most severe lesion was assigned.
Major bleed
• Major bleed was defined according to the ISTH definition 3 as: − Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or
Life-threatening bleed
• Life-threatening bleed was defined as: − Symptomatic intracranial bleed and/or reduction in hemoglobin of at least 5 g/dL and/or transfusion of at least 4 units of blood or packed cells, associated with hypotension requiring the use of i.v. inotropic agents and/or necessitating surgical intervention.
Intracranial hemorrhage
• Intracerebral, subdural, epidural, or subarachnoid hemorrhages.
Fatal bleeding
• Bleeding event that is the primary cause of death or contributing directly to death (as adjudicated by the adjudication committee).
Clinically relevant non-major bleeding events
• A clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, leading to at least 1 of the following: a hospital admission (at least 1 overnight stay) for bleeding; a physician-guided medical or surgical treatment for bleeding; a physician-guided change, interruption, or discontinuation of trial medication.
Any bleed
• Sum of all major and non-major bleeds.
